BioStem Technologies Uplists to Nasdaq, Trading Begins August 7
BSEM sits 36% above its 52-week low of $3.01 on elevated volume (4.2× avg).
Summary
BioStem Technologies uplisted to Nasdaq, with trading commencing August 7 under ticker BSEM. The move enhances market visibility and liquidity for the company, which faces near-term financial pressures including a going concern warning and a looming $10 million payment.
Key Events · Corporate Governance and Compliance · BSEM
-
Nasdaq Uplisting Effective
BioStem's common stock began trading on the Nasdaq Capital Market on August 7, 2026, under ticker BSEM, transitioning from the OTC.
-
Improved Market Visibility
The uplisting is expected to enhance liquidity, broaden the investor base, and improve access to capital — important for a company with a going concern warning and an $8.8M Q1 loss.
-
Near-Term Financial Pressure
The listing comes just days before an August 13 deadline to pay up to $10 million for the Catalyze wound care device, with the company's cash position strained.
-
No Shareholder Action Required
Existing shareholders do not need to take any action; the ticker symbol remains BSEM.
Analysis · BSEM · Life Sciences
BioStem Technologies' common stock begins trading on the Nasdaq Capital Market today, transitioning from the OTC. The uplisting is a significant milestone for the micro-cap regenerative medicine company, which recently disclosed a going concern warning and an $8.8 million Q1 loss. Nasdaq listing improves visibility and liquidity, potentially broadening the investor base and easing future capital raises — critical given the company's cash needs and the upcoming $10 million payment deadline for the Catalyze device on August 13.
At the time of this filing, BSEM was trading at $4.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $73M. The 52-week trading range was $3.01 to $10.71. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.